INFUGEM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9241948 | SUN PHARM | Ready to be infused gemcetabine solution |
Jul, 2033
(9 years from now) | |
Infugem is owned by Sun Pharm.
Infugem contains Gemcitabine Hydrochloride.
Infugem has a total of 1 drug patent out of which 0 drug patents have expired.
Infugem was authorised for market use on 16 July, 2018.
Infugem is available in solution;intravenous dosage forms.
The generics of Infugem are possible to be released after 01 July, 2033.
Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 July, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
INFUGEM family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic